Olr226 inhibitors represent a specialized class of compounds targeting the Olfactory receptor 226 (Olr226), a G protein-coupled receptor predominantly associated with olfactory sensory neurons. This receptor, like other members of the olfactory receptor family, is involved in the detection and transduction of odorant molecules, playing a crucial role in the sense of smell. Olr226 inhibitors are designed to specifically interact with the active sites or key functional domains of the Olr226 protein, thereby modulating its activity. The molecular architecture of Olr226 inhibitors typically involves a diverse array of chemical frameworks, ranging from small organic molecules to more complex structures that mimic endogenous ligands. These inhibitors can function through various mechanisms, such as competitive binding to the receptor's active site or by allosterically altering the receptor's conformation, which in turn affects its ability to bind to natural odorants.
The development and study of Olr226 inhibitors are of significant interest in the broader field of chemical biology and molecular pharmacology, particularly for understanding receptor-ligand interactions at a molecular level. By analyzing how these inhibitors affect Olr226, researchers gain insights into the structural and functional dynamics of olfactory receptors, contributing to the broader knowledge of sensory biology. This research involves sophisticated techniques, including X-ray crystallography, molecular docking, and computational modeling, to elucidate the binding modes and structural conformations of Olr226 in the presence of inhibitors. Moreover, the study of Olr226 inhibitors can also lead to the discovery of novel chemical motifs and scaffolds that may serve as molecular probes, further advancing our understanding of olfactory receptor function and regulation. The exploration of these inhibitors underscores the importance of targeted chemical modulation in deciphering the complex mechanisms underlying olfactory perception.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Beta-adrenergic antagonist, might modulate GPCR activity, potentially affecting Olr226. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Beta-adrenergic antagonist with alpha-1 blocking activity, could influence Olr226 signaling. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Alpha-2 adrenergic receptor antagonist, may affect GPCR signaling pathways related to Olr226. | ||||||
Labetalol | 36894-69-6 | sc-484723 | 50 mg | $180.00 | ||
Combined alpha and beta blocker, could indirectly affect GPCR pathways including Olr226. | ||||||
Pindolol | 13523-86-9 | sc-204847 sc-204847A | 100 mg 1 g | $194.00 $760.00 | ||
Beta-adrenergic antagonist, may influence GPCR-mediated signaling pathways related to Olr226. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Beta-adrenergic agonist, could indirectly affect Olr226 through GPCR modulation. | ||||||
Atropine | 51-55-8 | sc-252392 | 5 g | $204.00 | 2 | |
Muscarinic acetylcholine receptor antagonist, may influence GPCR signaling pathways including Olr226. | ||||||
Salmeterol | 89365-50-4 | sc-224277 sc-224277A | 10 mg 50 mg | $186.00 $562.00 | 1 | |
Beta-2 adrenergic agonist, potentially affecting GPCR pathways related to Olr226. | ||||||
Alprenolol | 13655-52-2 | sc-507469 | 50 mg | $130.00 | ||
Beta blocker, could indirectly influence GPCR signaling pathways including Olr226. | ||||||